Main Uses and Benefits of Nourianz

Nourianz (istradefylline) is an add-on treatment used for adults with Parkinson’s disease who are experiencing "off" episodes. These episodes occur when a patient's standard medication, typically levodopa/carbidopa, is not working optimally, leading to a return of Parkinson's symptoms such as tremors, stiffness, and difficulty moving.

Addressing "Off" Episodes

The primary purpose of Nourianz is to reduce the total amount of daily "off" time. In Parkinson’s disease, as the condition progresses, the effects of primary medications may wear off before the next dose is due, or they may take longer to start working. By acting on adenosine receptors in the brain rather than directly on dopamine receptors, Nourianz offers a different mechanism of action to help stabilize motor function throughout the day.

Clinical Benefits

In clinical studies, the integration of Nourianz into existing treatment regimens demonstrated specific benefits for patients managed on levodopa/carbidopa:

• Reduction in "Off" Time: Patients often see a decrease in the duration of daily "off" periods, allowing for more predictable symptom control.
• Increase in "On" Time: The reduction in "off" episodes typically corresponds with an increase in "on" time—periods where symptoms are well-controlled—without an increase in troublesome involuntary movements (dyskinesia).
• Support of Motor Function: By modulating the signaling pathways in the basal ganglia, the medication helps improve the overall consistency of movement and physical coordination.

Regulatory References

1. DailyMed (National Library of Medicine) Nourianz Label

Eligibility Map: Who Can and Cannot Use Nourianz — Official Regulatory Information

---

Eligibility Scope

Classification	Population Group	Regulatory Status
Allowed	Adults with Parkinson's disease on levodopa	Indicated Use
Contraindicated	Patients with a major psychotic disorder	Should not be treated
Contraindicated	Severe hepatic impairment (Child-Pugh C)	Avoid Use
Contraindicated	Concomitant use with strong CYP3A4 inducers	Avoid Use
Restricted	Moderate hepatic impairment (Child-Pugh B)	Max dosage limitation
Not Established	Pediatric patients (Under 18 years)	Safety and effectiveness not established
Not Recommended	Pregnancy	May cause fetal harm (animal data)
Conditional Use	Lactation/Breastfeeding	Unknown if excreted in human milk
Conditional Use	Heavy tobacco smokers (ge 20 cigarettes/day)	Requires adjusted dosage

---

Resulting Eligibility Structure

The official labeling defines Nourianz as being primarily for adult patients receiving levodopa therapy. Use is prohibited or must be avoided in patients with severe liver dysfunction, a major psychotic disorder, or those taking specific strong enzyme-inducing medications. Furthermore, its use is not established in children, and it is not recommended during pregnancy due to potential fetal harm. Patients with moderate hepatic impairment or those who smoke heavily require special consideration based on their physiological constraints.

Nourianz (istradefylline) is primarily metabolized by the CYP3A4 enzyme, which is the basis for several clinically significant interactions requiring dosage management.

Drug Interactions Requiring Dose Adjustment or Avoidance

• Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors, such as ketoconazole, significantly increases the exposure of istradefylline. When used with a strong CYP3A4 inhibitor, the maximum recommended dose of Nourianz is 20 mg once daily.
• Strong CYP3A4 Inducers: Products that strongly induce CYP3A4, such as carbamazepine, phenytoin, rifampin, or St. John's wort, are expected to decrease istradefylline exposure, potentially reducing its effectiveness. The use of Nourianz with strong CYP3A4 inducers must be avoided.
• Tobacco Smoking: Heavy tobacco smokers (20 or more cigarettes per day or equivalent) experience decreased istradefylline exposure due to CYP1A2 induction. For this population, the dose must be increased to 40 mg once daily to maintain adequate drug levels.

Interactions with Parkinson's Disease Medications

• Levodopa: When Nourianz is used as an adjunct to levodopa, it may cause or worsen existing dyskinesia (uncontrolled, sudden movements). This is a common side effect observed in clinical trials.
• Impulse Control/Compulsive Behaviors: Patients treated with Nourianz alongside one or more medications for Parkinson's disease, including levodopa, may experience new or increased intense urges, such as compulsive gambling or hypersexuality.

Selective Adenosine A2 A Receptor Blockade

The drug’s mechanism is based on selective antagonism of the Adenosine A2 A Receptors (A2 AR). These receptors, which function as inhibitory neuromodulators, are heavily expressed on specific neurons within the brain’s motor control center, primarily the striatum (part of the basal ganglia). By blocking A2 AR, the molecule prevents the binding of the endogenous neuromodulator Adenosine, thereby removing a physiological 'brake' imposed by Adenosine on these motor signaling pathways.

---

Indirect Modulation of the Basal Ganglia Circuit

The A2 AR are functionally linked to Dopamine D2 Receptors (D2R), a component of the indirect motor pathway that normally suppresses movement. The A2 AR antagonism releases the inhibitory constraint on the D2R, which functionally boosts the responsiveness of this pathway to dopamine. This action causes a rebalancing of the activity between the 'Go' and 'No-Go' systems in the basal ganglia, resulting in a rebalancing of motor regulation.

---

Functional Synergy with Dopaminergic Signaling

Nourianz operates as a non-dopaminergic therapy that creates synergy with the brain’s existing dopamine, including that supplied by levodopa. The mechanistic cascade results in an indirect enhancement of dopamine signaling. This potentiation means that the remaining or available dopamine can generate a stronger functional signal at the receptor level, leading to a sustained functional dopamine signal over time.

How Nourianz Is Used

Nourianz (istradefylline) is an oral film-coated tablet intended for continuous, long-term use as an adjunctive treatment to levodopa-based regimens. The instructions for administration establish a straightforward, once-daily pattern.

---

Official Administration Guidelines

Feature	Guideline Details
Route of Administration	Oral (by mouth), using the available 20 mg and 40 mg film-coated tablets.
Dosing Schedule	Recommended Starting Dose: 20 mg once daily.
	Maximum Daily Dose: 40 mg once daily.
Frequency & Timing	Taken once daily; may be administered with or without food.
Missed Dose Rule	If a dose is missed, the patient should skip the missed dose and take the next dose at the regularly scheduled time; do not take a double dose to compensate.

---

Population-Specific Use Restrictions

Dose adjustments are required based on individual patient factors:

• Hepatic Impairment: The maximum daily dose is restricted to 20 mg in patients with moderate liver impairment (Child-Pugh B). Use of the medicine should be avoided in patients with severe hepatic impairment.
• Tobacco Smokers: For patients who use 20 or more cigarettes per day (or equivalent), the recommended daily dosage is 40 mg.
• Co-Administration with Inhibitors: The maximum dose is restricted to 20 mg once daily when used concurrently with strong CYP3A4 inhibitors.

These guidelines define the standardized approach to using the medicine.

Research Evidence / Overview of Studies for Nourianz

Evidence for Use in Motor Fluctuations (Off Episodes)

The research on Nourianz has primarily focused on its use as an adjunctive treatment for adults with Parkinson's Disease who experience "Off" episodes while taking levodopa. The core evidence is derived from short-term, randomized, placebo-controlled trials (RCTs).

These studies primarily monitored the change in the total daily time spent in the "Off" state using patient diaries, and changes in "On" time without troublesome involuntary movements. Pooled analyses contributed to the contextual understanding of patient-reported experiences. The research reported findings related to the measured "Off" time compared to the placebo groups in the studies.

Long-Term Studies and Extended Follow-up

The main efficacy trials examining Nourianz were typically short-term, spanning only 12 to 16 weeks. Long-term outcomes are not well characterized by this initial controlled data.

Subsequent open-label extension studies were conducted, providing observational data related to "Off" time over extended study periods (up to a year or more). Research describes patterns observed in these longer observational settings.

Evidence in Specific Patient Groups

The research primarily examined highly pretreated populations—adult patients with established Parkinson’s Disease already receiving levodopa and experiencing motor complications. The findings from these studies are primarily applicable to this specific group. Data for groups in the early stages of PD or those not on levodopa remain insufficient.

Research on Patients with Pre-Existing Dyskinesia

Specific studies examined whether having existing dyskinesia at the start of the trial was associated with differences in the measured changes in "Off" or "On" time. Reports described that measured patterns were noted regardless of whether or not the patients had pre-existing dyskinesia.

Limitations and Research Uncertainties

The evidence highlights certain limitations where certainty remains low. The follow-up durations were limited in the pivotal controlled trials, and the full set of international Phase 3 findings were mixed, noting inconsistent findings across all trials.

Since the research consistently applied to patients on levodopa with fluctuating symptoms, the results apply only to the populations studied. Research is ongoing to better characterize long-term outcomes and examine evidence related to its use across the spectrum of the condition.

Key Studies & References Istradefylline: A novel agent in the treatment of ''off'' episodes associated with levodopa/carbidopa use in Parkinson disease

Common questions about Nourianz (FAQ)

Q: What's the difference between Nourianz and other add-on Parkinson's treatments?

A: Official information states that Nourianz is a Selective Adenosine A2 A Receptor Antagonist. This mechanism is non-dopaminergic, meaning the drug does not directly act on the dopamine system. Instead, it indirectly enhances dopamine signaling, which is pharmacologically distinct from other common add-on treatments for Parkinson's disease.

Q: How long does it typically take for Nourianz to start working?

A: Clinical studies that measured effectiveness against placebo typically spanned 12 to 16 weeks. Steady-state concentrations of the drug in the body are generally achieved after approximately two weeks of once-daily dosing. The full therapeutic effect is evaluated over time by a healthcare professional.

Q: What are the most common side effects people report on social media?

A: According to official regulatory documents, the most common side effects observed in clinical trials included dyskinesia (uncontrolled movements), dizziness, constipation, nausea, hallucinations, and problems sleeping (insomnia). These effects were reported more often in patients taking Nourianz than in those taking a placebo.

Q: Can Nourianz cause sleepiness or drowsiness during the day?

A: The most common side effect related to sleep is insomnia, or difficulty sleeping. While daytime sleepiness or drowsiness is not listed among the most common adverse reactions, other central nervous system effects like dizziness or fatigue have been reported as less common side effects.

Q: What should I do if I experience an unusual side effect while on Nourianz?

A: Patients are advised to contact a healthcare professional immediately for medical advice about side effects. Regulatory agencies also provide avenues for patients to report adverse events, such as the FDA in the United States.

Q: Why would my doctor choose Nourianz over a MAO-B inhibitor?

A: Nourianz works by blocking the Adenosine A2 A receptor, offering a distinct, non-dopaminergic mechanism. This differs from a MAO-B inhibitor, which slows the breakdown of dopamine. The decision to use one treatment over another is made by a healthcare professional based on the individual patient’s specific clinical needs.

Q: Is it normal to feel a bit nauseous when you first start taking Nourianz?

A: Nausea is listed in the official prescribing information as one of the most common adverse reactions reported in clinical trials. Because it is a frequently reported event, experiencing nausea is common for patients taking Nourianz.

Q: What is the best time of day to take Nourianz?

A: Nourianz is approved to be taken once daily and can be administered with or without food. Official guidelines do not mandate a specific time of day (morning or evening), allowing flexibility in the dosing schedule.

Q: If Nourianz works, how will I know it's effective for me?

A: Official information indicates that Nourianz's effectiveness is measured by a significant reduction in the daily time spent in the 'Off' state. Clinically, this is intended to help patients experience more 'On' time with improved motor control.

Q: Is Nourianz suitable for people with early-stage Parkinson's?

A: Nourianz is formally indicated as an add-on treatment for adults with Parkinson's disease who are already taking levodopa and experiencing motor fluctuations ('Off' episodes). Data for patients who are not taking levodopa or who are in the early stages of the condition remain insufficient to establish suitability.

Q: Does Nourianz affect the eyesight or vision?

A: Official labeling reports hallucinations (which may be visual) as a common side effect of the medicine. However, no specific changes to the eyes or other vision problems (such as blurred vision) are listed among the most common adverse reactions.

Q: Is it normal for the effect to wear off near the next dose time?

A: Nourianz has a relatively long elimination half-life of over 60 hours, and it is taken only once daily. This pharmacokinetic profile is intended to provide a sustained effect that carries over between doses, minimizing fluctuations.

Q: What happens if you suddenly stop taking Nourianz?

A: While the official prescribing information does not describe a formal withdrawal syndrome, official guidelines for managing an overdose suggest treatment includes discontinuing Nourianz. Patients are always advised to consult a healthcare professional before making any changes to their medication regimen.

Q: What is the risk of Nourianz interacting with over-the-counter supplements?

A: Nourianz is processed by the CYP3A4 enzyme, and regulatory information states that the use of strong enzyme inducers must be avoided. This includes the herbal supplement St. John's wort, as it can decrease the effectiveness of Nourianz.

Q: Is it safe to drink coffee or other caffeine products while taking Nourianz?

A: Official information does not list a major interaction between Nourianz and caffeine. Since caffeine also acts on adenosine receptors, patients should discuss all caffeine habits and consumption with their healthcare provider.

Q: Can Nourianz interact with common heart medications?

A: Many heart medications, along with other drugs, can affect the CYP3A4 enzyme that metabolizes Nourianz. Official guidance emphasizes informing a healthcare professional about all prescription and over-the-counter medicines taken to screen for potential interactions.

Q: Is there a generic version of Nourianz available?

A: Nourianz is the brand name for the active ingredient istradefylline. At this time, there is no FDA-approved generic version of the medicine available in the United States.

Q: Do you have to take Nourianz at the same time every day?

A: Nourianz is recommended to be taken once daily. For continuous treatment, it is generally recommended to take the dose at a similar time each day to help maintain consistent drug levels.

Q: Is Nourianz considered a controlled substance?

A: No. Istradefylline (Nourianz) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies.

Q: Why do some people report feeling tired after taking Nourianz?

A: Tiredness or fatigue is not listed as one of the most common adverse effects in regulatory documents. However, officially reported side effects such as insomnia (sleep problems) and dizziness are related to the central nervous system and could indirectly contribute to a feeling of fatigue.

Q: What is the effect of Nourianz on dyskinesia?

A: Official warnings state that when Nourianz is used as an add-on to levodopa, it is a recognized risk that it may cause or worsen existing dyskinesia (uncontrolled, involuntary movements). Dyskinesia was reported as the most common adverse reaction in clinical trials.

Q: Does Nourianz interact with alcohol?

A: Official information may not list a major drug interaction with alcohol. However, as alcohol is a central nervous system depressant, combining it with Nourianz could potentially increase side effects such as dizziness. Any alcohol consumption should be discussed with a healthcare professional.

Q: How is Nourianz eliminated from the body?

A: After being processed by liver enzymes, Nourianz is eliminated from the body primarily through feces, accounting for about two-thirds of the drug. A smaller portion of the drug is eliminated through the urine.

Q: What are the chances of developing a rash while on Nourianz?

A: A skin rash is listed in the official safety information as a less common side effect. The labeling also advises that the drug carries a risk of severe allergic reactions, which may include symptoms such as a rash, itching, or hives.

Storage and Disposal Requirements for Nourianz

The storage and disposal of Nourianz (istradefylline) must strictly adhere to the conditions mandated by the official regulatory labeling.

Requirement	Official Statement
Storage Temperature	Store at Controlled Room Temperature, which is 68 F to 77 F (20 C to 25 C). Acceptable temporary excursions range from 59 F to 86 F (15 C to 30 C).
Container Rule	Store the tablets in the original container as dispensed.
Child Protection	The medicine must be kept out of the reach of children.
Disposal Guidance	For unused or expired product, individuals should ask a healthcare professional or pharmacist for proper disposal instructions.

Storing the product at the specified Controlled Room Temperature is mandatory to maintain its labeled chemical stability and quality. There are no explicit instructions for protection from light or moisture beyond the standard temperature control. Disposal requires consultation with a professional, as the drug is not on the list for mandatory flushing, and general guidance applies to minimize environmental risk.